Ondansetron NDC 68462-105

NDC codes

FDA NDC Directory

Product NDC (as listed)68462-105Labeler and product segments. Claims need a package NDC.

Product NDC at billing width68462-0105Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
68462-105-30	68462010530	30 TABLET, FILM COATED in 1 BOTTLE (68462-105-30)Marketed from Jun 25, 2007
68462-105-33	68462010533	1 BLISTER PACK in 1 CARTON (68462-105-33) / 3 TABLET, FILM COATED in 1 BLISTER PACKMarketed from Jun 25, 2007

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Ondansetron
Generic name (nonproprietary): ondansetron
Active ingredients: Ondansetron hydrochloride — 4 mg/1
Dosage form: Tablet, Film coated
Route: Oral
Labeler: Glenmark Pharmaceuticals Inc., USA
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 077535
Marketing start: Jun 25, 2007
Listing expires: Dec 31, 2027
Other FDA classes: Serotonin 3 Receptor Antagonists (Mechanism)
Identifiers: Product ID 68462-105_32177a6a-8c35-4e1c-b7f5-7376b1c1316aSPL ID 32177a6a-8c35-4e1c-b7f5-7376b1c1316aSPL set ID eee5217a-eba8-463a-812d-bf3c66f0934fRxCUI 104894, 198052, 312086, 312087UNII NMH84OZK2B, 4AF302ESOSUPC 0368462157138, 0368462106303, 0368462105306, 0368462158111
Pharmacologic class: Serotonin-3 Receptor Antagonist

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N468462010530 followed by a unit qualifier and the quantity

Package 68462-0105-30. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jan 8, 2026.

Indications (excerpt from the label)

Ondansetron is indicated for the prevention of nausea and vomiting associated with: • highly emetogenic cancer chemotherapy, including cisplatin greater than or equal to 50 mg/m 2 • initial and repeat courses of moderately emetogenic cancer chemotherapy • radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen Ondansetron is also indicated for the prevention of postoperative nausea and/or vomiting. Ondansetron is a 5-HT 3 receptor antagonist indicated for the prevention of: • nausea and vomiting associated with highly emetogenic cancer chemotherapy, including cisplatin greater than or equal to 50 mg/m 2 . (…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 077535

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 077535
Product	Strength	Form · route	Labeler	Product NDC
Ondansetron	Ondansetron hydrochloride 4 mg/1	Tablet, Film coatedOral	Redpharm Drug	67296-2119
Ondansetron	Ondansetron hydrochloride 8 mg/1	Tablet, Film coatedOral	Glenmark Pharmaceuticals Inc., USA	68462-106
Ondansetron	Ondansetron hydrochloride 8 mg/1	Tablet, Film coatedOral	PD-Rx Pharmaceuticals, Inc.	43063-770